The Role of Sodium-Glucose Cotransporter 2 Inhibitors in the Management of Type 2 Diabetes

被引：18

作者：

Steen, Oren ^{[1
]}

Goldenberg, Ronald M. ^{[2
]}

机构：

[1] LMC Diabet & Endocrinol, 1929 Bayview Ave,Suite 107, Toronto, ON M4G 3E8, Canada

[2] LMC Diabet & Endocrinol, Thornhill, ON, Canada

来源：

CANADIAN JOURNAL OF DIABETES | 2017年 / 41卷 / 05期

关键词：

type; 2; diabetes; sodium-glucose cotransporter 2 inhibitors; cardiovascular safety; canagliflozin; dapagliflozin; empagliflozin; INADEQUATE GLYCEMIC CONTROL; DOUBLE-BLIND; SGLT2; INHIBITORS; BLOOD-PRESSURE; ADD-ON; KIDNEY-DISEASE; EMPAGLIFLOZIN; DAPAGLIFLOZIN; SAFETY; EFFICACY;

D O I：

10.1016/j.jcjd.2017.08.241

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Sodium-glucose cotransporter 2 (SGTL2) inhibitors are a novel class of antihyperglycemic agents that work in an insulin-independent manner by promoting urinary glucose excretion. In addition to efficacious glucose lowering, they exert beneficial effects on blood pressure and weight while avoiding hypoglycemia unless combined with insulin or insulin secretagogues. This review explores the mechanism of action of SGLT2 inhibitors, their effects on glycated hemoglobin, weight, blood pressure and hypoglycemia, potential adverse effects, renal considerations and cardiovascular outcomes. (C) 2017 Canadian Diabetes Association.

引用

页码：517 / 523

页数：7

共 73 条

[1]

[Anonymous], 2016, INV CAN TABL 100 MG

[2]

[Anonymous], 2016, FORX DAP TABL DAP PR

[3]

[Anonymous], 2013, CAN J DIABETES S3, V37, pS357

[4]

[Anonymous], 2015, SUMM SAF REV SOD GLU

[5]

[Anonymous], 2010, JARD EMP TABL 10 MG

[6]

AstraZeneca, 2012, MULT TRIAL EV EFF DA

[7] Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial [J].

Barnett, Anthony H. ;

Mithal, Ambrish ;

Manassie, Jenny ;

Jones, Russell ;

Rattunde, Henning ;

Woerle, Hans J. ;

Broedl, Uli C. .

LANCET DIABETES & ENDOCRINOLOGY, 2014, 2 (05) :369-384

[8] Sodium glucose co-transport 2 inhibitors in the treatment of type 2 diabetes mellitus: a meta-analysis of randomized double-blind controlled trials [J].

Berhan, Asres ;

Barker, Alex .

BMC ENDOCRINE DISORDERS, 2013, 13

[9] Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin [J].

Bilezikian, John P. ;

Watts, Nelson B. ;

Usiskin, Keith ;

Polidori, David ;

Fung, Albert ;

Sullivan, Daniel ;

Rosenthal, Norm .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2016, 101 (01) :43-50

[10] Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin [J].

Bolinder, Jan ;

Ljunggren, Osten ;

Kullberg, Joel ;

Johansson, Lars ;

Wilding, John ;

Langkilde, Anna Maria ;

Sugg, Jennifer ;

Parikh, Shamik .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (03) :1020-1031

← 1 2 3 4 5 6 7 8 →